In Donna Scroggin, v. Wyeth, and its divisions; Pharmacia & Upjohn Company L.L.C., (Case Nos: 08-2555, 08-2711 and 08-2713) on appeal from the United States District Court for the Eastern District of Arkansas, the plaintiff had sued the companies for failing to warn her that taking combinations of estrogen and progestin hormone therapy drugs manufactured by the defendants would put her at risk for breast cancer, which she developed 11 years after she began taking the drugs.
Thursday, November 05, 2009
Pfizer - Premarin/Prempro: 8th Circuit Affirms Arkansas Court Ruling in Products Liability Case
The U.S. Court of Appeals for the 8th Circuit has upheld Arkansas district court decisions in a products liability case against pharmaceutical companies that are the makers of hormone therapy drugs that, combined, have been linked to breast cancer.
In Donna Scroggin, v. Wyeth, and its divisions; Pharmacia & Upjohn Company L.L.C., (Case Nos: 08-2555, 08-2711 and 08-2713) on appeal from the United States District Court for the Eastern District of Arkansas, the plaintiff had sued the companies for failing to warn her that taking combinations of estrogen and progestin hormone therapy drugs manufactured by the defendants would put her at risk for breast cancer, which she developed 11 years after she began taking the drugs.
In Donna Scroggin, v. Wyeth, and its divisions; Pharmacia & Upjohn Company L.L.C., (Case Nos: 08-2555, 08-2711 and 08-2713) on appeal from the United States District Court for the Eastern District of Arkansas, the plaintiff had sued the companies for failing to warn her that taking combinations of estrogen and progestin hormone therapy drugs manufactured by the defendants would put her at risk for breast cancer, which she developed 11 years after she began taking the drugs.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment